Advertisement
Canada markets closed

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7319
    -0.0001 (-0.02%)
     

  • CRUDE OIL

    83.34
    -0.02 (-0.02%)
     

  • Bitcoin CAD

    90,984.20
    -175.25 (-0.19%)
     

  • CMC Crypto 200

    1,435.39
    +20.63 (+1.46%)
     

  • GOLD FUTURES

    2,337.50
    -4.60 (-0.20%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,735.25
    +128.50 (+0.73%)
     

  • VOLATILITY

    15.69
    -1.25 (-7.38%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    38,329.39
    +777.23 (+2.07%)
     

  • CAD/EUR

    0.6835
    -0.0001 (-0.01%)
     

DEADLINE TODAY: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses In Excess of $500,000 to Contact the Firm

ACCESSWIRE

LOS ANGELES, CA / ACCESSWIRE / October 17, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Depomed, Inc. ("Depomed" or the "Company") (DEPO) for possible violations of federal securities laws from February 26, 2015 through August 7, 2017, inclusive (the "Class Period"). Investors, who purchased or otherwise acquired Depomed shares during the Class Period, should contact the firm by October 17, 2017, the lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.

ADVERTISEMENT

The Complaint alleges that, during the Class Period, Depomed made false and/or misleading statements, and/or failed to disclose: that the Company engaged in questionable practices in connection with the sales and marketing of its opioid products; that this conduct would likely subject Depomed to heightened legal and regulatory scrutiny; and that as a result of the above, the Company's public statements were materially false and misleading at all relevant times.

On August 7, 2017, Depomed revealed that it "recently received a request for information from the ranking minority member of the United States Senate Committee on Homeland Security and Governmental Affairs related to the promotion of opioids" and that Depomed also received "subpoenas related to opioid sales and marketing from the Office of the Attorney General of Maryland and the United States Department of Justice." Following this news, Depomed's stock price fell materially, which caused investors harm according to the lawsuit.

Lundin Law PC was established by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC